Full history for every metric is available with a Kvantra account
Lumos Pharma, Inc. (LUMO)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 0 | 0 | 2 | 2 | 2 |
| Operating profit | $m | -37 | -36 | |||||
| Net profit | $m | -54 | -43 | -6 | -30 | -31 | -34 | -35 |
| EPS reported | $ | -4.18 | -4.29 | |||||
| Operating cashflow per share | $ | -3.82 | -3.82 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -3.82 | -3.82 | |||||
| Free cash flow | $m | -31 | -45 | |||||
| Net debt | $m | -36 | -14 | |||||
| Book value equity | $m | 27 | - | |||||
| Book value per share | $ | 3.35 | - | |||||
| Number of shares | m | 8.15 | 8.33 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.95 | 1.29 | |||||
| P/S LTM | x | 12.63 | 17.02 | |||||
| P/FCF LTM | x | -0.83 | -0.84 | |||||
| EV/EBITDA LTM | x | 0.23 | -0.66 | |||||
| EV/Sales LTM | x | -4.19 | 10.89 | |||||
| Earnings Yield LTM | % | -131.40% | -96.28% | |||||
| FCF Yield | % | -120.05% | -119.56% | |||||
| Quality | ||||||||
| ROE | % | -124.64% | -78.34% | |||||
| ROIC | % | -107.95% | -107.95% | |||||
| Operating margin | % | -1785.2% | -1785.2% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -1516.1% | -1516.1% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +34.67% | +26.94% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -53.15 | -260.92 | |||||
| Net Debt/EBITDA | x | 0.94 | 0.94 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -139.28% | -36.02% | |||||
| Net debt/Equity | x | -1.32 | - | |||||
| Gross debt/equity | x | 0.02 | - | |||||
Company overview
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lumos Pharma, Inc. (LUMO)
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free